Arnold Lippa

10.3k total citations · 1 hit paper
91 papers, 8.5k citations indexed

About

Arnold Lippa is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Cognitive Neuroscience. According to data from OpenAlex, Arnold Lippa has authored 91 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Cellular and Molecular Neuroscience, 38 papers in Molecular Biology and 16 papers in Cognitive Neuroscience. Recurrent topics in Arnold Lippa's work include Neuroscience and Neuropharmacology Research (57 papers), Receptor Mechanisms and Signaling (21 papers) and Neurotransmitter Receptor Influence on Behavior (18 papers). Arnold Lippa is often cited by papers focused on Neuroscience and Neuropharmacology Research (57 papers), Receptor Mechanisms and Signaling (21 papers) and Neurotransmitter Receptor Influence on Behavior (18 papers). Arnold Lippa collaborates with scholars based in United States, Slovenia and Poland. Arnold Lippa's co-authors include Bernard Beer, Raymond T. Bartus, Reginald L. Dean, Claire A. Klepner, Mary Sano, B. Beer, Joseph Coupet, D.J. Critchett, Phil Skolnick and Laurence R. Meyerson and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

Arnold Lippa

90 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Cholinergic Hypothesis of Geriatric Memory Dysfunction

1982 4.5k citations Bernard Beer, Arnold Lippa et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Arnold Lippa United States	34	4.6k	3.1k	2.7k	2.4k	1.2k	91	8.5k
Giancarlo Pepeu Italy	58	5.4k 1.2×	3.9k 1.2×	3.0k 1.1×	2.3k 1.0×	2.0k 1.6×	245	10.4k
Bernard Beer United States	30	4.6k 1.0×	3.1k 1.0×	2.7k 1.0×	2.5k 1.0×	1.4k 1.1×	58	8.8k
Jerry J. Buccafusco United States	51	3.0k 0.7×	4.0k 1.3×	2.3k 0.9×	1.3k 0.6×	1.6k 1.3×	200	8.3k
Alvin V. Terry United States	52	2.8k 0.6×	3.8k 1.2×	2.0k 0.7×	1.2k 0.5×	1.1k 0.9×	205	8.7k
Arjan Blokland Netherlands	58	4.7k 1.0×	4.3k 1.4×	2.7k 1.0×	2.4k 1.0×	1.6k 1.3×	236	11.6k
Chris G. Parsons Germany	45	5.7k 1.2×	3.6k 1.1×	1.9k 0.7×	1.2k 0.5×	2.5k 2.1×	146	9.3k
Wojciech Danysz Germany	58	8.7k 1.9×	4.7k 1.5×	2.0k 0.7×	2.1k 0.9×	2.3k 1.9×	228	12.7k
Guy A. Higgins Canada	60	5.9k 1.3×	3.8k 1.2×	1.2k 0.4×	1.6k 0.7×	1.6k 1.3×	153	9.1k
Gary L. Wenk United States	57	4.0k 0.9×	2.9k 0.9×	2.1k 0.8×	2.7k 1.1×	2.1k 1.7×	159	9.0k
Frank P. Bymaster United States	57	6.6k 1.4×	5.0k 1.6×	3.1k 1.2×	1.6k 0.7×	1.4k 1.1×	141	12.7k

Countries citing papers authored by Arnold Lippa

Since Specialization

Citations

This map shows the geographic impact of Arnold Lippa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnold Lippa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnold Lippa more than expected).

Fields of papers citing papers by Arnold Lippa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnold Lippa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnold Lippa. The network helps show where Arnold Lippa may publish in the future.

Co-authorship network of co-authors of Arnold Lippa

This figure shows the co-authorship network connecting the top 25 collaborators of Arnold Lippa. A scholar is included among the top collaborators of Arnold Lippa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnold Lippa. Arnold Lippa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Radin, Daniel P., Rok Cerne, Jodi L. Smith, Jeffrey M. Witkin, & Arnold Lippa. (2025). Antipsychotic-like pharmacological profile of the low impact ampakine CX691 (farampator): Implications for the use of low impact ampakines in the treatment of schizophrenia. Journal of Psychiatric Research. 186. 145–153. 1 indexed citations

Witkin, Jeffrey M., Daniel P. Radin, Sabhya Rana, et al.. (2024). AMPA receptors play an important role in the biological consequences of spinal cord injury: Implications for AMPA receptor modulators for therapeutic benefit. Biochemical Pharmacology. 228. 116302–116302. 7 indexed citations

Radin, Daniel P., Sheng Zhong, Rok Cerne, et al.. (2024). Low-Impact Ampakine CX1739 Exerts Pro-Cognitive Effects and Reverses Opiate-Induced Respiratory Depression in Rodents. SHILAP Revista de lepidopterología. 4(1). 173–187. 12 indexed citations

Radin, Daniel P., Rok Cerne, Jeffrey M. Witkin, & Arnold Lippa. (2024). High-Impact AMPAkines Elevate Calcium Levels in Cortical Astrocytes by Mobilizing Endoplasmic Reticular Calcium Stores. SHILAP Revista de lepidopterología. 5(3). 344–355. 1 indexed citations

Rana, Sabhya, Jeffrey M. Witkin, Daniel P. Radin, et al.. (2024). Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy. Pharmacology & Therapeutics. 265. 108744–108744. 3 indexed citations

Radin, Daniel P., Sheng Zhong, Rok Cerne, Jeffrey M. Witkin, & Arnold Lippa. (2024). High Impact AMPAkines Induce a Gq‐Protein Coupled Endoplasmic Calcium Release in Cortical Neurons: A Possible Mechanism for Explaining the Toxicity of High Impact AMPAkines. Synapse. 78(5). e22310–e22310. 1 indexed citations

Cerne, Rok, et al.. (2024). Nonsedating anxiolytics. Pharmacology Biochemistry and Behavior. 245. 173895–173895. 1 indexed citations

Ping, Xingjie, Lalit K. Golani, Xiaoming Jin, et al.. (2023). Comparative anticonvulsant activity of the GABAkine KRM‐II‐81 and a deuterated analog. Drug Development Research. 84(3). 601–605. 2 indexed citations

Witkin, Jeffrey M. & Arnold Lippa. (2023). Potentiation of AMPA receptors for rapid therapeutic gain in psychiatry has reached a new level of excitement. Neuropsychopharmacology. 49(1). 339–340. 5 indexed citations

10.

Golani, Lalit K., Rok Cerne, Jodi L. Smith, et al.. (2022). Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3‐selective GABAkine KRM‐II‐81. Biopharmaceutics & Drug Disposition. 43(2). 66–75. 5 indexed citations

11.

Radin, Daniel P., et al.. (2018). Ampakines Attenuate Staurosporine-induced Cell Death in Primary Cortical Neurons: Implications in the ‘Chemo-Brain’ Phenomenon. Anticancer Research. 38(6). 3461–3465. 8 indexed citations

12.

Radin, Daniel P., et al.. (2018). Oncolytic Properties of Ampakines In Vitro. Anticancer Research. 38(1). 265–269. 10 indexed citations

13.

Radin, Daniel P., et al.. (2018). Stargazin differentially modulates ampakine gating kinetics and pharmacology. Biochemical Pharmacology. 148. 308–314. 4 indexed citations

14.

Radin, Daniel P., et al.. (2018). Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain. Biomedicine & Pharmacotherapy. 105. 540–544. 22 indexed citations

15.

Czobor, Pál, Phil Skolnick, Bernard Beer, & Arnold Lippa. (2009). A Multicenter, Placebo‐Controlled, Double‐Blind, Randomized Study of Efficacy and Safety of Ocinaplon (DOV 273,547) in Generalized Anxiety Disorder. CNS Neuroscience & Therapeutics. 16(2). 63–75. 23 indexed citations

16.

Skolnick, Phil, Philip A. Krieter, Joseph P. Tizzano, et al.. (2006). Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor. CNS Drug Reviews. 12(2). 123–134. 88 indexed citations

17.

Popik, Piotr, Martyna Krawczyk, Krystyna Gołembiowska, et al.. (2006). Pharmacological Profile of the “Triple” Monoamine Neurotransmitter Uptake Inhibitor, DOV 102,677. Cellular and Molecular Neurobiology. 26(4-6). 855–871. 30 indexed citations

18.

Skolnick, Phil, Piotr Popik, Aaron Janowsky, Bernard Beer, & Arnold Lippa. (2003). Antidepressant-like actions of DOV 21,947: a “triple” reuptake inhibitor. European Journal of Pharmacology. 461(2-3). 99–104. 117 indexed citations

19.

Lippa, Arnold, Bernard Beer, & Robert Cancro. (1999). Introduction. Overview of Citalopram. Journal of Clinical Psychopharmacology. 19(5 Suppl 1). 1S–3S. 1 indexed citations

20.

Lippa, Arnold, Laurence R. Meyerson, & Bernard Beer. (1982). Molecular substrates of anxiety: Clues from the heterogeneity of benzodiazepine receptors. Life Sciences. 31(14). 1409–1417. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact